Raymond James Financial Services Advisors Inc. Sells 546 Shares of The Chemours Company (NYSE:CC)

Raymond James Financial Services Advisors Inc. trimmed its stake in shares of The Chemours Company (NYSE:CCGet Rating) by 0.5% during the 3rd quarter, Holdings Channel.com reports. The fund owned 101,814 shares of the specialty chemicals company’s stock after selling 546 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Chemours were worth $2,510,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Asset Management One Co. Ltd. bought a new stake in shares of Chemours in the second quarter worth about $25,000. CNB Bank bought a new stake in shares of Chemours in the 2nd quarter worth approximately $25,000. Trust Co. of Vermont bought a new position in shares of Chemours during the second quarter valued at approximately $35,000. Ellevest Inc. lifted its stake in Chemours by 34,325.0% in the second quarter. Ellevest Inc. now owns 1,377 shares of the specialty chemicals company’s stock worth $44,000 after acquiring an additional 1,373 shares during the period. Finally, GPS Wealth Strategies Group LLC boosted its holdings in Chemours by 82.9% in the second quarter. GPS Wealth Strategies Group LLC now owns 1,655 shares of the specialty chemicals company’s stock valued at $53,000 after acquiring an additional 750 shares in the last quarter. 71.89% of the stock is owned by hedge funds and other institutional investors.

Chemours Trading Up 0.9 %

NYSE:CC opened at $33.58 on Monday. The Chemours Company has a 52 week low of $22.56 and a 52 week high of $44.95. The stock has a market cap of $5.07 billion, a price-to-earnings ratio of 5.99, a PEG ratio of 0.67 and a beta of 1.84. The company’s 50 day moving average price is $31.47 and its 200-day moving average price is $31.57. The company has a quick ratio of 1.14, a current ratio of 1.82 and a debt-to-equity ratio of 2.73.

Chemours (NYSE:CCGet Rating) last posted its earnings results on Tuesday, October 25th. The specialty chemicals company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.08. The business had revenue of $1.80 billion during the quarter, compared to analyst estimates of $1.67 billion. Chemours had a return on equity of 73.45% and a net margin of 12.91%. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.27 EPS. On average, equities research analysts forecast that The Chemours Company will post 4.74 earnings per share for the current fiscal year.

Chemours Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, December 15th. Shareholders of record on Tuesday, November 15th were paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 2.98%. The ex-dividend date was Monday, November 14th. Chemours’s dividend payout ratio is currently 17.83%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Royal Bank of Canada cut shares of Chemours from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $35.00 to $33.00 in a research report on Tuesday, January 10th. Credit Suisse Group started coverage on Chemours in a research report on Tuesday, November 1st. They issued an “underperform” rating and a $24.00 target price for the company. The Goldman Sachs Group started coverage on Chemours in a research note on Thursday, October 13th. They issued a “neutral” rating and a $30.00 target price for the company. Citigroup upped their price target on Chemours from $30.00 to $33.00 and gave the stock a “neutral” rating in a research note on Thursday, December 15th. Finally, Argus cut shares of Chemours from a “buy” rating to a “hold” rating in a report on Wednesday, October 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $32.90.

Chemours Profile

(Get Rating)

The Chemours Co is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial.

Recommended Stories

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CCGet Rating).

Institutional Ownership by Quarter for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.